https://scholars.lib.ntu.edu.tw/handle/123456789/554459
標題: | Hyperreflective foci in predicting the treatment outcomes of diabetic macular oedema after anti-vascular endothelial growth factor therapy | 作者: | Huang C.-H. CHANG-HAO YANG YI-TING HSIEH CHUNG-MAY YANG TZYY-CHANG HO TSO-TING LAI |
公開日期: | 2021 | 出版社: | Nature Research | 卷: | 11 | 期: | 1 | 起(迄)頁: | 5103 | 來源出版物: | Scientific Reports | 摘要: | This retrospective study evaluated the association of hyperreflective foci (HRF) with treatment response in diabetic macular oedema (DME) after anti-vascular endothelial growth factor (VEGF) therapy. The medical records, including of ophthalmologic examinations and optical coherence tomography (OCT) images, of 106 patients with DME treated with either intravitreal ranibizumab or aflibercept were reviewed. The correlations between best-corrected visual acuity (BCVA) changes and HRF along with other OCT biomarkers were analysed. The mean logMAR BCVA improved from 0.696 to 0.461 after an average of 6.2 injections in 1?year under real-world conditions. Greater visual-acuity gain was noted in patients with a greater number of HRF in the outer retina at baseline (p = 0.037), along with other factors such as poor baseline vision (p < 0.001), absence of epiretinal membrane (p = 0.048), and presence of subretinal fluid at baseline (p = 0.001). The number of HRF after treatment was correlated with the presence of hard exudate (p < 0.001) and baseline haemoglobin A1C (p = 0.001). Patients with proliferative diabetic retinopathy had greater HRF reduction after treatment (p = 0.018). The number of HRF in the outer retina, in addition to other baseline OCT biomarkers, could be used to predict the treatment response in DME after anti-VEGF treatment. ? 2021, The Author(s). |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102016058&doi=10.1038%2fs41598-021-84553-7&partnerID=40&md5=c7021e922c7eebe0faa6cdc234a4acc9 https://scholars.lib.ntu.edu.tw/handle/123456789/554459 |
ISSN: | 2045-2322 | DOI: | 10.1038/s41598-021-84553-7 | SDG/關鍵字: | aflibercept; angiogenesis inhibitor; fusion protein; ranibizumab; vasculotropin; vasculotropin receptor; aged; complication; diabetic retinopathy; diagnostic imaging; female; follow up; human; intravitreal drug administration; macular edema; male; middle aged; optical coherence tomography; pathophysiology; procedures; prognosis; retina; retrospective study; Taiwan; treatment outcome; visual acuity; Aged; Angiogenesis Inhibitors; Diabetic Retinopathy; Female; Follow-Up Studies; Humans; Intravitreal Injections; Macular Edema; Male; Middle Aged; Prognosis; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retina; Retrospective Studies; Taiwan; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factors; Visual Acuity |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。